Analyst Price Target is $17.00
▲ +245.53% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 245.53% upside from the last price of $4.92.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Cara Therapeutics. This Buy consensus rating has held steady for over two years.
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.